Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Price, News & Analysis

Ambrx Biopharma logo

About Ambrx Biopharma Stock (NYSE:AMAM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$27.70
$28.00
52-Week Range
N/A
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Remove Ads
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
14 Day AMERIBOR Average Rate (^AMBRX)
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
See More Headlines

AMAM Stock Analysis - Frequently Asked Questions

Ambrx Biopharma (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ambrx Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

Today
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NYSE:AMAM
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.40 million
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
N/A

Miscellaneous

Free Float
62,746,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
-1.92
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:AMAM) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners